Clinical trial
Endothelial Modulation for Angiogenic Therapy
NCT00134433 · Ottawa Heart Institute Research Corporation, Other · Completed
Key facts
| NCT number | NCT00134433 |
|---|---|
| Title | Endothelial Modulation for Angiogenic Therapy |
| Official title | Endothelial Modulation With L-Arginine in Patients Undergoing Angiogenic Therapy (EMAT): A 2x2 Factorial Trial |
| Lead sponsor | Ottawa Heart Institute Research Corporation, Other |
| Collaborators | Heart and Stroke Foundation of Ontario |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Coronary Artery Disease |
| Intervention type | Drug, Genetic |
| Interventions | intramyocardial VEGF angiogenesis (at a dose of 2 mg), oral L-arginine supplementation (at a dose of 6 g/day) |
| Enrollment | 20 |
| Start date | Nov 1, 2004 |
| Primary completion | Mar 1, 2007 |
| Completion | Oct 1, 2007 |
| First posted | Aug 24, 2005 |
| Last update posted | Jun 21, 2012 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: